Clinical trials for a vaccine made from a patient's blood and tumor showed promise in high-risk melanoma patients, according to the vaccine's developer, Elios Therapeutics. The vaccine sparks the patient's T-cells and immune system to destroy the cells.
Vaccine shows promise for patients with high-risk melanoma
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.